Skip to main content
SpringerLink
Log in

Personalized Medicine: Integrating Individual Exposure and Response Information at the Bedside

  • Chapter
  • First Online:
Applied Pharmacometrics

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 14))

Abstract

Over the years, the use of therapeutic agents has progressed from administering the same dose, to progressively more complex dosing approaches, in an attempt to personalize treatment. Personalized medicine is based on the concept of tailoring treatment based in part on patient characteristics predictive of response to therapy, thereby improving efficacy and limiting toxicity. However, integrating this information into an appropriate dose for a specific patient is a complex process that requires the development of decision support systems. Dashboard systems offer an improved, convenient means of tailoring treatment for individual patients, particularly for drugs with high variability in exposure, a complex relationship between exposure and response (both beneficial and harmful), or a narrow therapeutic window. We provide an overview of the concept and application of dashboard systems.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson BJ, Holford NH (2013) Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 98(9):737–744

    Article  PubMed  Google Scholar 

  • Baert F, Noman M, Vermeire S, Van Assche G, D’Haens G, Carbonez A, Rutgeerts P (2003) Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N Engl J Med 348(7):601–608

    Article  CAS  PubMed  Google Scholar 

  • Barrett JS, Mondick JT, Narayan M, Vijayakumar K, Vijayakumar S (2008) Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy. BMC Med Inform Decis Mak 8:6

    Article  PubMed Central  PubMed  Google Scholar 

  • Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430

    CAS  PubMed  Google Scholar 

  • Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD (2010) Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making 30(3):328–340

    Article  PubMed  Google Scholar 

  • Coppack SW (2001) Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 60(3):349–356

    Article  CAS  PubMed  Google Scholar 

  • Dashboard development and data visualization tools for effective BI (2014) http://searchcio.techtarget.com/definition/dashboard. Accessed 22 Aug 2014

  • Domínguez Hernández KR, Aguilar Lasserre AA, Posada Gómez R, Palet Guzmán JA, González Sánchez BE (2013) Development of an expert system as a diagnostic support of cervical cancer in atypical glandular cells, based on fuzzy logics and image interpretation. Comput Math Methods Med 2013:796–387

    Article  Google Scholar 

  • Egorin MJ (2003) Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. J Clin Oncol 21(2):182–183

    Article  PubMed  Google Scholar 

  • Elliott G, Granger CWJ, Timmermann AG (2006) Handbook of economic forecasting, vol 1, Chap. 1. Elsevier, Netherlands

    Google Scholar 

  • Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H (2009) Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 65(12):1211–1228

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM (2010) Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 48(5):297–308

    Article  CAS  PubMed  Google Scholar 

  • Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM (2011) Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 33(7):946–964

    Article  CAS  PubMed  Google Scholar 

  • García MJ, Gavira R, Santos Buelga D, Dominguez-Gil A (1994) Predictive performance of two phenytoin pharmacokinetic dosing programs from nonsteady state data. Ther Drug Monit 16:380–387

    Article  PubMed  Google Scholar 

  • Gill J (2008) Bayesian methods: a social and behavioral sciences approach, 2nd edn. Chapman and Hall Boca Raton, Florida, pp. 56–60

    Google Scholar 

  • Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078932.pdf. Accessed 3 Sept 2014

  • Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN (2007) A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 81(4):529–538

    Article  CAS  PubMed  Google Scholar 

  • Hamberg AK, Friberg LE, Hanséus K, Ekman-Joelsson BM, SunnegÃ¥rdh J, Jonzon A, Lundell B, Jonsson EN, Wadelius M (2013) Warfarin dose prediction in children using pharmacometric bridging–comparison with published pharmacogenetic dosing algorithms. Eur J Clin Pharmacol 69(6):1275–1283

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Ho WR, Germain MJ, Garb J, Picard S, Mackie MK, Bartlett C, Will EJ (2010) Use of 12x/month haemoglobin monitoring with a computer algorithm reduces haemoglobin variability. Nephrol Dial Transplant 25(8):2710–2714

    Article  CAS  PubMed  Google Scholar 

  • Hoeting JA, Madigan D, Raftery AE, Volinsky CT (1999) Bayesian model averaging: a tutorial. Stat Sci 14(4):382–417

    Article  Google Scholar 

  • Holford SD, Holford NHG, Anderson BJ Online dose calculation tool for determining dosing regimens in the very young. http://www.paganz.org/sites/default/files/slides/Admin/Online%20dose%20calculation%20tool%20for%20determining%20dosing%20regimens%20in%20the%20very%20young.pdf. Accessed 23 Aug 2014

  • Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359–364

    Article  CAS  PubMed  Google Scholar 

  • Lesko LJ, Schmidt S (2012) Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther 92(4):458–466

    CAS  PubMed  Google Scholar 

  • Maser EA, Villela R, Silverberg MS, Greenberg GR (2006) Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol 4(10):1248–1254

    Article  CAS  PubMed  Google Scholar 

  • Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB (2009) Medical directors of dialysis clinic Inc. Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis 54(6):1081–1088

    Article  PubMed Central  PubMed  Google Scholar 

  • Mohan M, Batty KT, Cooper JA, Wojnar-Horton RE, Ilett KF (2004) Comparison of gentamicin dose estimates derived from manual calculations, the Australian ‘Therapeutic guidelines: antibiotic’ nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol 58:521–527

    Article  PubMed Central  PubMed  Google Scholar 

  • Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. Bio Drugs 24(1):23–39

    CAS  Google Scholar 

  • Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation and model based drug development. CPT: Pharmacometrics Syst Pharmacol 1:e6

    CAS  Google Scholar 

  • Mould DR, Moyer B, Amur S, Mukherjee A (2013) The impact of new technologies on the science of clinical care and drug development. AAPS Magazine, December

    Google Scholar 

  • Mould DR, Upton R, Wojciechowski J (2014) Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside. AAPS J ePub June 2014

    Google Scholar 

  • Nestorov I (2005) Clinical pharmacokinetics of tumor necrosis factor antagonists. J Rheumatol Suppl 74:13–18

    CAS  PubMed  Google Scholar 

  • Ordás I, Mould DR, Feagan BG, Sandborn WJ (2012) Monoclonal antibodies in inflammatory bowel disease: pharmacokinetic based dosing paradigms. Clin Pharmacol Ther 91(4):635–646

    Article  PubMed  Google Scholar 

  • Papier A (2012) Decision support in dermatology and medicine: history and recent developments. Semin Cutan Med Surg 31(3):153–159

    Article  CAS  PubMed  Google Scholar 

  • Perlstein TS, Goldhaber SZ, Nelson K, Joshi V, Morgan TV, Lesko LJ, Lee JY, Gobburu J, Schoenfeld D, Kucherlapati R, Freeman MW, Creager MA (2012) The creating an optimal warfarin nomogram (CROWN) study. Thromb Haemost 107(1):59–68

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF (2008) Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 6(6):644–653

    Article  CAS  PubMed  Google Scholar 

  • Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL et al (2009) Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 68(11):1739–1745

    Article  CAS  PubMed  Google Scholar 

  • Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hörtnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Müller CR, Strom TM, Oldenburg J (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537–541

    Article  CAS  PubMed  Google Scholar 

  • Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR (2010) Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59(1):49–54

    Article  CAS  PubMed  Google Scholar 

  • Sivyer A (1959) A dose-rate calculator. Br J Radiol 32(375):208–209

    Article  CAS  PubMed  Google Scholar 

  • Takahashi H, Echizen H (2003) Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Pharmacogenomics J 3:202–214

    Article  CAS  PubMed  Google Scholar 

  • Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30(4):523–529

    CAS  PubMed  Google Scholar 

  • Tobler A, Mühlebach S (2013) Intravenous phenytoin: a retrospective analysis of Bayesian forecasting versus conventional dosing in patients [published online ahead of print 29 June 2013]. Int J Clin Pharm. doi:10.1007/s11096-013-9809-5

    Google Scholar 

  • Usman M, Ashraf M, Khokhar MI et al (2013) Comparative pharmacokinetics of levofloxacin in healthy volunteers and in patients suffering from typhoid Fever. Iran J Pharm Res 12:147–154

    CAS  PubMed Central  PubMed  Google Scholar 

  • Wong C, Kumar SS, Graham GG, Begg EJ, Chin PK, Brett J, Ray JE, Marriott DJ, Williams KM, Day RO (2013) Comparing dose prediction software used to manage gentamicin dosing. Intern Med J 43:519–525

    Article  CAS  PubMed  Google Scholar 

  • Xu Z, Mould DR, Hu C, Ford J, Keen M, Davis HM, Zhou H (2012) A population-based pharmacokinetic pooled analysis of infliximab in pediatrics. ACCP national meeting, San Diego CA

    Google Scholar 

  • Xu Z, Davis HM, Zhou H (2013) Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther 137(2):225–247

    Article  CAS  PubMed  Google Scholar 

  • Zineh I, Huang S-M (2011) Biomarkers in drug development and regulation: a paradigm for clinical implementation of personalized medicine. Biomark Med 5(6):705–713

    Article  CAS  PubMed  Google Scholar 

Download references

Author Contributions

The authors contributed equally to the manuscript.

Author information

Authors and Affiliations

  1. Projections Research, Phoenixville, PA, USA

    Diane R. Mould PhD

  2. Center for Pharmacometrics and Systems Pharmacology, University of Florida, Orlando, FL, USA

    Lawrence J Lesko PhD

Authors
  1. Diane R. Mould PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lawrence J Lesko PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diane R. Mould PhD .

Editor information

Editors and Affiliations

  1. University of Florida, Department of Pharmaceutics, Center for Pharmacometrics & Systems Pharmacology, Orlando, Florida, USA

    Stephan Schmidt

  2. University of Florida, College of Pharmacy, Department of Pharmaceutics, Gainesville, Florida, USA

    Hartmut Derendorf

Rights and permissions

Reprints and permissions

Copyright information

© 2014 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Mould, D., Lesko, L. (2014). Personalized Medicine: Integrating Individual Exposure and Response Information at the Bedside. In: Schmidt, S., Derendorf, H. (eds) Applied Pharmacometrics. AAPS Advances in the Pharmaceutical Sciences Series, vol 14. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-1304-6_2

Download citation

Publish with us

Policies and ethics

Search

Navigation